156 related articles for article (PubMed ID: 35622165)
1. NOTCH gene alterations in metastatic colorectal cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN).
Kajiwara T; Nishina T; Nakasya A; Yamashita N; Yamashita R; Nakamura Y; Shiozawa M; Yuki S; Taniguchi H; Hara H; Ohta T; Esaki T; Shinozaki E; Takashima A; Moriwaki T; Denda T; Ohtsubo K; Sunakawa Y; Horita Y; Kawakami H; Kato T; Satoh T; Ando K; Mizutani T; Yasui H; Goto M; Okuyama H; Yamazaki K; Yoshino T; Hyodo I
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2841-2854. PubMed ID: 35622165
[TBL] [Abstract][Full Text] [Related]
2. Sidedness-Dependent Prognostic Impact of Gene Alterations in Metastatic Colorectal Cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN).
Kajiwara T; Nishina T; Yamashita R; Nakamura Y; Shiozawa M; Yuki S; Taniguchi H; Hara H; Ohta T; Esaki T; Shinozaki E; Takashima A; Yamamoto Y; Yamazaki K; Yoshino T; Hyodo I
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958346
[TBL] [Abstract][Full Text] [Related]
3. Fecal gene detection based on next generation sequencing for colorectal cancer diagnosis.
He SY; Li YC; Wang Y; Peng HL; Zhou CL; Zhang CM; Chen SL; Yin JF; Lin M
World J Gastroenterol; 2022 Jul; 28(25):2920-2936. PubMed ID: 35978873
[TBL] [Abstract][Full Text] [Related]
4. NOTCH3 signaling regulates MUSASHI-1 expression in metastatic colorectal cancer cells.
Pastò A; Serafin V; Pilotto G; Lago C; Bellio C; Trusolino L; Bertotti A; Hoey T; Plateroti M; Esposito G; Pinazza M; Agostini M; Nitti D; Amadori A; Indraccolo S
Cancer Res; 2014 Apr; 74(7):2106-18. PubMed ID: 24525742
[TBL] [Abstract][Full Text] [Related]
5. Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy.
Mizukami T; Takahashi M; Sunakawa Y; Yuki S; Kagawa Y; Takashima A; Kato K; Hara H; Denda T; Yamamoto Y; Shiozawa M; Oki E; Okamoto W; Yoshino T; Eguchi Nakajima T
Target Oncol; 2022 May; 17(3):343-353. PubMed ID: 35524872
[TBL] [Abstract][Full Text] [Related]
6. Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal Cancer.
Kawaguchi Y; Kopetz S; Kwong L; Xiao L; Morris JS; Tran Cao HS; Tzeng CD; Chun YS; Lee JE; Vauthey JN
J Am Coll Surg; 2021 Aug; 233(2):272-284.e13. PubMed ID: 34111531
[TBL] [Abstract][Full Text] [Related]
7. Multigene panel next generation sequencing in metastatic colorectal cancer in an Australian population.
Nindra U; Pal A; Lea V; Lim SH; Wilkinson K; Asghari R; Roberts TL; Becker TM; Farzin M; Rutland T; Lee M; MacKenzie S; Ng W; Wang B; Lee CS; Chua W
PLoS One; 2023; 18(10):e0292087. PubMed ID: 37796807
[TBL] [Abstract][Full Text] [Related]
8. Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan.
Ikoma T; Shimokawa M; Kotaka M; Matsumoto T; Nagai H; Boku S; Shibata N; Yasui H; Satake H
BMC Cancer; 2021 May; 21(1):518. PubMed ID: 33962575
[TBL] [Abstract][Full Text] [Related]
9. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.
Alonso-Espinaco V; Cuatrecasas M; Alonso V; Escudero P; Marmol M; Horndler C; Ortego J; Gallego R; Codony-Servat J; Garcia-Albeniz X; Jares P; Castells A; Lozano JJ; Rosell R; Maurel J
Eur J Cancer; 2014 Jul; 50(11):1973-81. PubMed ID: 24833563
[TBL] [Abstract][Full Text] [Related]
10. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
Chen J; Guo F; Shi X; Zhang L; Zhang A; Jin H; He Y
BMC Cancer; 2014 Nov; 14():802. PubMed ID: 25367198
[TBL] [Abstract][Full Text] [Related]
11. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
Løes IM; Immervoll H; Sorbye H; Angelsen JH; Horn A; Knappskog S; Lønning PE
Int J Cancer; 2016 Aug; 139(3):647-56. PubMed ID: 26991344
[TBL] [Abstract][Full Text] [Related]
12. The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study.
Chida K; Kotani D; Masuishi T; Kawakami T; Kawamoto Y; Kato K; Fushiki K; Sawada K; Kumanishi R; Shirasu H; Matsubara Y; Yuki S; Komatsu Y; Yamazaki K; Yoshino T
Oncologist; 2021 Oct; 26(10):845-853. PubMed ID: 34232546
[TBL] [Abstract][Full Text] [Related]
13. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
[TBL] [Abstract][Full Text] [Related]
14. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review.
Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G
Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887
[TBL] [Abstract][Full Text] [Related]
16.
Garcia-Carbonero N; Martinez-Useros J; Li W; Orta A; Perez N; Carames C; Hernandez T; Moreno I; Serrano G; Garcia-Foncillas J
Cells; 2020 Jan; 9(1):. PubMed ID: 31952366
[No Abstract] [Full Text] [Related]
17. Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program.
Nakamura Y; Yamashita R; Okamoto W; Komatsu Y; Yuki S; Ueno M; Kato K; Taniguchi H; Kagawa Y; Denda T; Hara H; Esaki T; Moriwaki T; Sunakawa Y; Oki E; Nagashima F; Nishina T; Satoh T; Kawakami H; Yamaguchi K; Ohtsubo K; Kato T; Horita Y; Tsuji A; Yasui H; Goto M; Hamamoto Y; Wakabayashi M; Ikeno T; Shitara K; Bando H; Tsuchihara K; Miki I; Ichiki H; Ohtsu A; Yoshino T
JCO Precis Oncol; 2023 Mar; 7():e2200653. PubMed ID: 36996376
[TBL] [Abstract][Full Text] [Related]
18. Nuclear Notch3 expression is associated with tumor recurrence in patients with stage II and III colorectal cancer.
Ozawa T; Kazama S; Akiyoshi T; Murono K; Yoneyama S; Tanaka T; Tanaka J; Kiyomatsu T; Kawai K; Nozawa H; Kanazawa T; Yamaguchi H; Ishihara S; Sunami E; Kitayama J; Morikawa T; Fukayama M; Watanabe T
Ann Surg Oncol; 2014 Aug; 21(8):2650-8. PubMed ID: 24728738
[TBL] [Abstract][Full Text] [Related]
19. Mutational analysis of NOTCH1, 2, 3 and 4 genes in common solid cancers and acute leukemias.
Lee SH; Jeong EG; Yoo NJ; Lee SH
APMIS; 2007 Dec; 115(12):1357-63. PubMed ID: 18184405
[TBL] [Abstract][Full Text] [Related]
20. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.
Smith JC; Brooks L; Hoff PM; McWalter G; Dearden S; Morgan SR; Wilson D; Robertson JD; Jürgensmeier JM
Eur J Cancer; 2013 Jul; 49(10):2424-32. PubMed ID: 23510802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
